Patent Litigation Europe Agenda | Kisaco Research
Agenda Days: 
  • Tuesday, 20 Jan, 2026

    Cross-Border Pharmaceutical Patent Litigation Cases and the Effect Upon Your IP Strategy

    Cross-border litigation poses unique challenges and opportunities for the pharmaceutical and biotech industries. This panel will explore the complexities of managing patent litigation across multiple jurisdictions, strategies for harmonizing legal approaches, and the impact of international regulatory environments.


    • Review the major cross-border case law and discuss the resulting IP effects from decisions such as: Tecfidera, Apixaban, Rivaroxaban, Glucose monitoring device cases, Paxlovid and Jardiance.
    • Discuss common challenges faced in cross-border patent litigation, including jurisdictional issues, differing legal standards, and enforcement of judgments.
    • Understand strategies for harmonising litigation approaches and minimising conflicting decisions.

    Speaker(s): 

    Author:

    Daniel Lim

    Partner
    Kirkland & Ellis

    Daniel Lim

    Partner
    Kirkland & Ellis

    Author:

    Elisabeth Haselhorst

    IP Litigation Counsel
    Bayer

    Elisabeth Haselhorst

    IP Litigation Counsel
    Bayer

    Author:

    Laila Beynon

    Director – Dispute Resolution
    Regeneron

    Laila Beynon is Director, Dispute Resolution at Regeneron, responsible for the strategic co-ordination of ex-US patent litigation. She has a PhD in Biochemistry/Molecular Biology, 10 years’ private practice experience in life sciences patent litigation at Herbert Smith Freehills LLP, and prior to her role at Regeneron headed up the Patent Litigation team at BAT. 

    Laila Beynon

    Director – Dispute Resolution
    Regeneron

    Laila Beynon is Director, Dispute Resolution at Regeneron, responsible for the strategic co-ordination of ex-US patent litigation. She has a PhD in Biochemistry/Molecular Biology, 10 years’ private practice experience in life sciences patent litigation at Herbert Smith Freehills LLP, and prior to her role at Regeneron headed up the Patent Litigation team at BAT. 

    Author:

    Raquel Frisardi

    Senior Corporate Counsel
    Novo Nordisk

    Raquel Frisardi

    Senior Corporate Counsel
    Novo Nordisk

    Author:

    Rob Rodrigues

    Partner
    RNA law

    Rob Rodrigues

    Partner
    RNA law

    Author:

    Katherine Helm

    Partner
    Dechert

    Katherine Helm

    Partner
    Dechert
    Agenda Track No.: 
    Track 1
    Session Type: 
    Panel

    Mediate, Arbitrate, License, Oppose or Litigate? Decisions for the Tech Sector

    Navigating intellectual property disputes requires strategic decisions on the most effective resolution paths. This session explores the full range of options available to tech companies—from mediation and arbitration to licensing, opposition, and litigation. Gain insight into when each tool is best suited, how to manage IP portfolios proactively, support innovation teams, and balance the operational and financial impact of disputes on your business.

    • Explore the expanding role of mediation and arbitration as faster, cost-effective alternatives to traditional litigation in various IP disputes.

    • Understand the potential impact of the new UPC Mediation and Arbitration Centre in Ljubljana, and how it may change dispute resolution for European patent holders and implementers.

    • Understand how strategic licensing and portfolio management can help avoid costly conflicts and support innovation.

    • Discuss when to escalate matters through opposition proceedings or litigation and how to prepare for large-scale enforcement campaigns globally.

    Speaker(s): 

    Author:

    Bas Van Buul

    Director of IP
    Inalfa Roof Systems

    Bas Van Buul

    Director of IP
    Inalfa Roof Systems

    Author:

    Jako Eleveld

    Head of IP Licensing
    Philips

    Jako Eleveld

    Head of IP Licensing
    Philips

    Author:

    Mitsuaki Masumura

    Head of Licensing AP & EMEA
    IBM

    Mitsuaki Masumura

    Head of Licensing AP & EMEA
    IBM
    Agenda Track No.: 
    Track 2
    Session Type: 
    General Session (Presentation)
Agenda Tracks: 
Track Title: 
Pharma & Biotech Patent Litigation Track
Track Color: 
#ff97d7
Track Title: 
Tech & Innovation Patent Litigation Track
Track Color: 
#c6d2fe